Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: Mutations of CDKN2 are observed preferentially in T lineage

Leukemia

Volumn 10, Issue 2, 1996, Pages 249-254

  Nakao, M ^a   Yokota, S ^a   Kaneko, H ^a   Seriu, T ^a   Koizumi, S ^b   Takaue, Y ^c   Fujimoto, T ^d   Misawa, S ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute lymphoblastic leukemia; CDKN2; Mutation; p16; Tumor suppressor gene

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FRAMESHIFT MUTATION; GENE MUTATION; GENE STRUCTURE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE;

EID: 0029994588     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chilcote RR, Brown E, Rowley JD. Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. New Engl J Med 1985; 313: 286-291.
2. Smith SD et al. Chromosome 9 abnormalities in childhood T-cell leukemia. New Engl J Med 1986; 313: 195-196.
3. Carrol AJ, Castleberry RP, Crist WM. Lack of association between abnormalities of the chromosome 9 short arm and either 'lymphomatous' feature or T cell phenotype in childhood acute lymphoblastic leukemia. Blood 1987; 69: 735-738.
4. Murphy SB et al. Nonrandom abnormalities of chromosome 9p in childhood acute lymphoblastic leukemia: association with high-risk clinical features. Blood 1989; 74: 409-415.
5. Uckun FM, Gajl-Peczalska KJ, Provisor AJ, Heerema NA. Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. Blood 1989; 73: 271-280.
6. Diaz MO et al. Deletion of interferon genes in acute lymphoblastic leukemia. New Engl J Med 1990; 322: 77-82.
7. Serrano M, Hannon GJ, Beach DA. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
8. Kamb A et al. A cell cycle regulator potentially involved in genes of many tumor types. Science 1994; 264: 436-440.
9. Nobori T et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756.
10. INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045-11049.
11. Spruck C III et al. p16 gene in uncultured tumours. Nature 1994; 370: 183-184.
12. Schultz DC et al. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 1995; 55: 2150-2157.
13. Mori T et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cycline-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396-3397.
14. INK4 expression is frequent in high grade gliomas. Cancer Res 1995; 55: 1941-1945.
15. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55: 1448-1451.
16. Cheng JQ et al. p16 alteration and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5551.
17. Lo K-W, Huang DP, Lau K-M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995; 55: 2039-2043.
18. Ogawa S et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemia. Blood 1994; 84: 2431-2435.
19. INK4B) display frequent homozygous deletions in primary cells from T but not from B cell lineage acute lymphoblastic leukemias. Blood 1994; 84: 4038-4044.
20. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995; 55. 1436-1440.
21. Quesnel B et al. p16 gene homozygous deletion in acute lymphoblastic leukemia Blood 1995; 85: 657-663.
22. INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood 1995, 85: 854
23. Stranks G et al. Deletions and rearrangement of CDKN2 in lymphoid malignancv. Blood 1995; 85: 893-901
24. INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995; 85: 2321-2330.
25. Fizzotti M et al. Detection of homozygous deletion of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995; 85: 2685-2690.
26. Sill H, Goldman JM, Cross NCP. Homozygous deletion of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013-2016.
27. ink4 gene inactivation in acute lymphocytic leukemia. Blood 1995; 85: 3431-3436.
28. Hatta Y et al. Homozygous deletion of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T cell leukemia. Blood 1995; 85: 2699-2704.
29. Seriu T et al. Prospective monitoring of minimal residual disease during course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. Leukemia 1995; 9: 615-623.
30. Bennett JM et al. The morphological classification of acute lymphoblastic leukemia; concordance among observers and clinical correlations. Br J Haematol 1981; 47: 553-561.
31. Yokota S et al. Use of polymerase chain reaction to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991; 77: 331-339.
32. Kakizuka A et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor. Cell 1991; 66: 663-674.
33. Cairns P et al. Rates of p16 (CDKN2) mutations in primary tumors with 9p loss. Science 1994; 265: 415-416.
34. Ohta M et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 1994; 54: 5269-5272.
35. ink4) in human breast carcinomas. Cancer Res 1994; 54: 5262-5264.
36. Beltinger CP et al. No CDKN2 mutations in neuroblastomas. Cancer Res 1995; 55: 2053-2055.
37. Koh J, Enders CH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375: 506-510.
38. Ohnishi H et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T cell acute lymphoblastic leukemia. Blood 1995; 86: 1269-1275.